الفهرس 
LACTOFERRIN OVERVIEWOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
Lactoferrin is an iron binding protein and one of the main component of breast milk that showed in the last decade very promising results in the prophylaxis against neonatal sepsis, NEC, fungal infections, anaemia of prematurity and infancy.
Our primary aim was to prove that LF has a beneficial effect in the prevention of IFIs in the preterm neonates in NICUs.
Our study was conducted on 40 preterm neonates in the NICUs of maternity and children hospitals, faculty of medicine, Ain Shams University in the period from March 2017 to May 2017.
The 40 neonates were subdivided into 2 groups:
- group A: 20 neonates who received LF in a dose of 100 mg/day for 4- 6 weeks starting from day of enrolment.
- group B: 20 neonates who received placebo in form of distilled water for 4-6 weeks staring from day of enrolment.
The neonates included in this study were subjected to full history taking; through clinical examination laying stress on clinical signs of infection and laboratory investigations, CBC with differential cell count, CRP, blood culture and fungal cultures that were withdrawn on day of enrolment, day 7, 14, 21 and 28.
Neonates with underlying gastrointestinal anomalies that prevent enteral intake, congenital anomalies, suspected inborn